Peijia Medical-B (09996) announced interim results with revenue of 425 million yuan, up 20.1% year-on-year

According to the Zhitong Finance App, Peijia Medical-B (09996) announced its 2026 interim results, with revenue of 425 million yuan, up 20.1% year on year; gross profit of 290 million yuan, up 17.13% year on year; and R&D expenditure of 884.09 million yuan.

The announcement stated that during the reporting period, the Group achieved continuous revenue growth. By continuously optimizing the product portfolio, implementing lean cost management measures, and improving operational efficiency, the Group partially offset the negative effects of TAVR price adjustments, higher manufacturing costs and neurointervention business collection in the early stages of the climb, while maintaining a steady gross profit margin of about 68.3%.

During the reporting period, the Group's self-developed neurointerventional products continued to receive market recognition, benefiting from differentiated product design, clinical value and innovative treatment plans. Through close collaboration between doctors and engineers, the Group has developed a range of innovative technologies and solutions. Among them, BASIS technology based on Syphonet® embolization stents and zero exchange technology based on FastTunnel® delivery balloon expansion catheters have been widely used clinically, further promoting market penetration of related products. Furthermore, DCWire® microguide wire continues to receive clinical approval, contributing to the growth of the Group's self-developed neurointerventional product portfolio.

At the same time, the Group continues to expand its portfolio of neurointerventional products through strategic cooperation. During the reporting period, the Group increased the commercialization scale of YonFlow® blood-flow guided dense mesh stents and Qida® disposable neural catheter sheaths in China and contributed to additional revenue growth. The Group also entered into a strategic cooperation agreement with Beylang Healthcare (Shanghai) International Trade Co., Ltd. (Beylang Healthcare) to cooperate on the exclusive distribution of SeQuent® Please CIS paclitaxel drug-coated intracranial balloon expansion catheters in mainland China, further enriching the pipeline of neurointerventional products and providing more opportunities for business growth after obtaining regulatory approval in the future.